Physician profile
Dennis Egitto
NPI 1629005061
$1,335.02
in general payments reported to CMS, 2019-2025
28 companies · $213 in 2025
The $213 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $385 · 2020: $115 · 2021: $127 · 2022: $88.19 · 2023: $242 · 2024: $166 · 2025: $213.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $620.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $620.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $156.18 | 2019-2025 | |
| Abbvie INC. | $155.32 | 2021-2024 | Vraylar, Ubrelvy, Qulipta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $103.92 | 2019-2023 | Xifaxan |
| Glaxosmithkline, LLC. | $96.13 | 2019-2025 | Arexvy, Shingrix |
| Janssen Pharmaceuticals, INC | $87.18 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $84.93 | 2024-2025 | Rexulti |
| Astrazeneca Pharmaceuticals LP | $78.91 | 2019-2025 | Breztri |
| Exact Sciences Corporation | $78.64 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Amarin Pharma, INC. | $48.00 | 2019 | |
| Novartis Pharmaceuticals Corporation | $43.69 | 2019 | |
| Amgen INC. | $36.26 | 2023-2025 | Krystexxa, Repatha, Otezla |
| Abbott Laboratories | $33.20 | 2022-2025 | Freestyle Libre 3 |
| Novo Nordisk INC | $30.09 | 2024-2025 | Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.09 | 2020 | |
| Almatica Pharma LLC | $27.53 | 2021-2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $27.12 | 2019 | |
| Arbor Pharmaceuticals, INC. | $23.72 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $23.23 | 2021 | |
| Azurity Pharmaceuticals, INC. | $23.17 | 2024 | Horizant |
| Supernus Pharmaceuticals, INC. | $22.05 | 2023 | Qelbree |
| Sebela Pharmaceuticals INC. | $19.11 | 2019 | |
| Mylan Specialty L.P. | $17.57 | 2023 | Yupelri |
| Braintree Laboratories, INC. | $17.57 | 2019 | |
| Csl Behring | $16.89 | 2025 | Hizentra |
| Paratek Pharmaceuticals, INC. | $15.98 | 2023 | Nuzyra |
| Indivior INC. | $15.75 | 2022 | |
| Eisai INC. | $12.99 | 2021 | |
| Antares Pharma, INC. | $11.80 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dennis Egitto listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.